Evaluation of patients’ attitudes towards stroke prevention and bleeding risk in atrial fibrillation

Summary

Patient’s values and preferences regarding the relative importance of preventing strokes and avoiding bleeding are now recognised to be of great importance in deciding on therapy for the prevention of stroke due to atrial fibrillation (SPAF). We used an iPad questionnaire to determine the minimal clinically important difference (Treatment Threshold) and the maximum number of major bleeding events that a patient would be willing to endure in order to prevent one stroke (Bleeding Ratio) for the initiation of antithrombotic therapy in 172 hospital in-patients with documented non-valvular atrial fibrillation in whom anticoagulant therapy was being considered. Patients expressed strong opinions regarding SPAF. We found that 12% of patients were “medication averse” and were not willing to consider antithrombotic therapy; even if it was 100% effective in preventing strokes. Of those patients who were willing to consider antithrombotic therapy, 42% were identified as “risk averse” and 15% were “risk tolerant”. Patients required at least a 0.8% (NNT=125) annual absolute risk reduction and 15% relative risk reduction in the risk of stroke in order to agree to initiate antithrombotic therapy, and patients were willing to endure 4.4 major bleeds in order to prevent one stroke. In conclusion, there was a substantial amount of inter-patient variability, and often extreme differences in opinion regarding tolerance of bleeding risk in the context of stroke prevention in atrial fibrillation. These findings highlight the importance of considering patient preferences when deciding on SPAF therapy.

Keywords

Atrial fibrillation - stroke prevention - antithrombotic - anticoagulation

• References

• 1 Camm AJ. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012; 33: 2719-2747.
• 2 Skanes AC. et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: Recommendations for stroke prevention and rate/ rhythm control. Can J Cardiol 2012; 28: 125-136.
• 3 Canadian Agency for Drugs and Technology for Health.. Recommendations for optimal warfarin management for prevention of thromboembolic events in patients with atrial fibrillation. http://cadth.ca/en/products/optimal-use/warfarin-management/reports. Accessed December 9, 2011.
• 4 LaHaye SA. et al. A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation. Eur Heart J 2012; 33: 2163-2171.
• 5 Devereaux PJ. et al. Differences between perspectives of physicians and patients on anticoagulation in patient patients with atrial fibrillation: observational study. Br Med J 2001; 323: 1-7.
• 6 Man-Son-Hing M. et al. Warfarin for atrial fibrillation. Arch Intern Med 1996; 156: 1841-1848.
• 7 Gage BF. et al. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med 1996; 156: 1829-1836.
• 8 Thomson R. et al. Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Lancet 2000; 355: 956-926.
• 9 Solomon NA. et al. Patient preferences for stroke outcomes. Stroke 1994; 25: 1721-1725.
• 10 Man-Son-Hing M. et al. Preference-based antithrombotic therapy in atrial fibrillation: Implications for clinical decision making. Med Decis Making 2005; 25: 548-559.
• 11 Clinical Support Systems.. ‘AFib Patient Kiosk’ iPad Application available in the iTunes App Store. (February 23, 2012).
• 12 Lip GYH. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest 2010; 137: 263-272.
• 13 Pisters R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation. Chest; 138: 1093-1100.
• 14 Torrance GW. Measurement of health state utilities for economic appraisal. J of Health Economics 1986; 5: 1-30.
• 15 Olesen JB. et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: A nationwide cohort study. Thromb Haemost 2012; 107: 1072-1079.
• 16 Naylor CD, Llewellyn-Thomas HA. Can there be a more patient-centred approach to determining clinically important effect sizes for randomized treatment trials?. J Clin Epidemiol 1994; 47: 787-795.
• 17 Pisters R. et al. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. Thromb Haemost 2013; 109: 328-336.
• 18 Clinical Support Systems.. ‘AFib CDA’ iPhone/iPad Application available in the iTunes App Store. (February 23, 2012).